LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/stat3/akt pathway

Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma

(2013) Yingjian Liang et al.   HEPATOLOGY

Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53

(2012) Tzu-Ching Kuo et al.   BIOCHEMICAL PHARMACOLOGY

The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines

(2012) M. Lemoine et al.   BLOOD

Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression

(2012) Yeong Hwa Kim et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Pan-Histone Deacetylase Inhibitor Panobinostat Sensitizes Gastric Cancer Cells to Anthracyclines via Induction of CITED2

(2012) Ivonne Regel et al.   GASTROENTEROLOGY

Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer

(2012) Yanjun Jiang et al.   HEPATOLOGY

Overexpression of a novel gene gankyrin correlates with the malignant phenotype of colorectal cancer

(2010) Shanhong Tang et al.   CANCER BIOLOGY & THERAPY

Gankyrin promotes the proliferation of human pancreatic cancer

(2010) Yun Meng et al.   CANCER LETTERS

Intracellular signaling and hepatocellular carcinoma

(2010) Polina Iakova et al.   SEMINARS IN CANCER BIOLOGY

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

(2009) H Miles Prince et al.   Future Oncology

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

(2009) Pippa Newell et al.   JOURNAL OF HEPATOLOGY